These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37151058)

  • 21. Kitlow stem cells cause resistance to Kit/platelet-derived growth factor alpha inhibitors in murine gastrointestinal stromal tumors.
    Bardsley MR; Horváth VJ; Asuzu DT; Lorincz A; Redelman D; Hayashi Y; Popko LN; Young DL; Lomberk GA; Urrutia RA; Farrugia G; Rubin BP; Ordog T
    Gastroenterology; 2010 Sep; 139(3):942-52. PubMed ID: 20621681
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular research directions in the management of gastrointestinal stromal tumors.
    Tarn C; Godwin AK
    Curr Treat Options Oncol; 2005 Nov; 6(6):473-86. PubMed ID: 16242052
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis.
    Lee JH; Kim Y; Choi JW; Kim YS
    J Gastrointestin Liver Dis; 2013 Dec; 22(4):413-8. PubMed ID: 24369323
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery and pharmacological characterization of AZD3229, a potent KIT/PDGFRα inhibitor for treatment of gastrointestinal stromal tumors.
    Banks E; Grondine M; Bhavsar D; Barry E; Kettle JG; Reddy VP; Brown C; Wang H; Mettetal JT; Collins T; Adeyemi O; Overman R; Lawson D; Harmer AR; Reimer C; Drew L; Packer MJ; Cosulich S; Jones RD; Shao W; Wilson D; Guichard S; Fawell S; Anjum R
    Sci Transl Med; 2020 Apr; 12(541):. PubMed ID: 32350132
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting the translational machinery in gastrointestinal stromal tumors (GIST): a new therapeutic vulnerability.
    Lee DM; Sun A; Patil SS; Liu L; Rao AV; Trent PT; Ali AA; Liu C; Rausch JL; Presutti LD; Kaczorowski A; Schneider F; Amankulor NM; Shuda M; Duensing A
    Sci Rep; 2022 May; 12(1):8275. PubMed ID: 35585158
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gastrointestinal stromal tumor and its targeted therapeutics.
    Dupart J; Zhang W; Trent JC
    Chin J Cancer; 2011 May; 30(5):303-14. PubMed ID: 21527063
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New insights into the clinical management of advanced gastrointestinal stromal tumors.
    Italiano A
    Expert Opin Pharmacother; 2021 Mar; 22(4):439-447. PubMed ID: 33307872
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors.
    Serrano C; George S; Valverde C; Olivares D; García-Valverde A; Suárez C; Morales-Barrera R; Carles J
    Target Oncol; 2017 Jun; 12(3):277-288. PubMed ID: 28478525
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Personalized Medicine in Gastrointestinal Stromal Tumor (GIST): Clinical Implications of the Somatic and Germline DNA Analysis.
    Ravegnini G; Nannini M; Sammarini G; Astolfi A; Biasco G; Pantaleo MA; Hrelia P; Angelini S
    Int J Mol Sci; 2015 Jul; 16(7):15592-608. PubMed ID: 26184165
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib.
    Nemunaitis J; Bauer S; Blay JY; Choucair K; Gelderblom H; George S; Schöffski P; Mehren MV; Zalcberg J; Achour H; Ruiz-Soto R; Heinrich MC
    Future Oncol; 2020 Jan; 16(1):4251-4264. PubMed ID: 31755321
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impressive long-term disease stabilization by nilotinib in two pretreated patients with KIT/PDGFRA wild-type metastatic gastrointestinal stromal tumours.
    Pantaleo MA; Nannini M; Saponara M; Gnocchi C; Di Scioscio V; Lolli C; Catena F; Astolfi A; Di Battista M; Biasco G;
    Anticancer Drugs; 2012 Jun; 23(5):567-72. PubMed ID: 22430048
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [New drug approvals: Ripretinib for advanced gastrointestinal stromal tumors (GIST) in fourth or later-line therapy].
    Lemaître J; Watson S
    Bull Cancer; 2022 Mar; 109(3):250-252. PubMed ID: 35094842
    [No Abstract]   [Full Text] [Related]  

  • 33. An updated review of the treatment landscape for advanced gastrointestinal stromal tumors.
    Patel SR; Reichardt P
    Cancer; 2021 Jul; 127(13):2187-2195. PubMed ID: 33974733
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors.
    Rossi S; Sbaraglia M; Dell'Orto MC; Gasparotto D; Cacciatore M; Boscato E; Carraro V; Toffolatti L; Gallina G; Niero M; Pilozzi E; Mandolesi A; Sessa F; Sonzogni A; Mancini C; Mazzoleni G; Romeo S; Maestro R; Dei Tos AP
    Oncotarget; 2016 May; 7(21):30109-18. PubMed ID: 27097112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor.
    Gounder MM; Maki RG
    Cancer Chemother Pharmacol; 2011 Jan; 67 Suppl 1(Suppl 1):S25-43. PubMed ID: 21116624
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New Tyrosine Kinase Inhibitors for the Treatment of Gastrointestinal Stromal Tumors.
    Serrano C; Bauer S
    Curr Oncol Rep; 2022 Feb; 24(2):151-159. PubMed ID: 35061196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Advanced GIST: Which treatments in 2022?].
    Mas L; Bachet JB
    Bull Cancer; 2022 Oct; 109(10):1082-1087. PubMed ID: 35934543
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Molecular mechanism and therapeutic strategy for resistance to tyrosine kinase inhibitors in targeted treatment of gastrointestinal stromal tumors].
    Xu J; Cao H
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):288-91. PubMed ID: 23536353
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New targets and therapies for gastrointestinal stromal tumors.
    Wozniak A; Gebreyohannes YK; Debiec-Rychter M; Schöffski P
    Expert Rev Anticancer Ther; 2017 Dec; 17(12):1117-1129. PubMed ID: 29110548
    [TBL] [Abstract][Full Text] [Related]  

  • 40. KIT/PDGFRA inhibitors for the treatment of gastrointestinal stromal tumors: getting to the gist of the problem.
    Cicala CM; Olivares-Rivas I; Aguirre-Carrillo JA; Serrano C
    Expert Opin Investig Drugs; 2024 Mar; 33(3):159-170. PubMed ID: 38344849
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.